WW Q2 2026 - Preliminary Earnings Alert

Event: Quartr Q2 2026 event Retrieved: 2026-08-05T20:35:00Z Comparison mode: maximal Scorecard contract: v1 Source status: release=available | financials=earnings release only | transcript=not available (call scheduled 2026-08-05 21:00Z)

Consensus scorecard

Reported results and guidance

Weight Watchers emerged from reorganization on 24 June 2025 and applied fresh start accounting. The prior-year quarter is therefore split into a Successor stub (25-30 June 2025) and a Predecessor period (30 March - 24 June 2025), and the release states the two bases are not comparable. Revenue is the one line the company itself presents on a combined basis.

Company-presented combined revenue comparison (fresh start adjustments do not affect revenue):

• Scorecard recap: revenue of $162.3m beat consensus by 2.0% and GAAP diluted EPS of $1.41 beat the $0.48 estimate by 193.8%.
• Q2 gross margin was 70.3% and adjusted gross margin 73.6%, which the release describes as near record highs.
• Q2 adjusted EBITDA was $39.8m; marketing expense was $47.9m, or 29.5% of revenue, down from $92.9m in Q1 2026 after peak season.
• Operating activities generated $24.3m of cash in the quarter.
• The company prepaid $36.8m of term loan principal in the quarter ($26.8m June annual cash sweep plus $10.0m in May at 68.5% of par), reducing outstanding principal by $41.4m and annualized interest expense by approximately $4m.
• Core+, the higher-value behavioral tier, ended the quarter at 541 thousand subscribers, up 13.9% year over year and the third consecutive quarter of sequential growth.
• The company is run by an Interim Office of the Chief Executive; Jon Volkmann (COO) and Felicia DellaFortuna (CFO) are the quoted executives and the CEO search is listed among the release's risk factors.

Key bullish aspects

• Both scorecard metrics beat: revenue by 2.0% and GAAP diluted EPS by 193.8%, the latter helped by an $11.155m tax benefit rather than by operations.
• Clinical subscription revenue grew 30.4% year over year to $39.9m and 31.1% for the six months to $78.7m, while clinical end-of-period subscribers grew 55.7% to 197 thousand — and the release notes this laps a prior-year quarter that included the company's former compounded semaglutide offering.
• Monthly subscription revenue per average subscriber rose 10.2% to $20.90, so mix shift toward clinical is lifting revenue per user even as the subscriber count falls.
• Core+ posted its third consecutive quarter of sequential subscriber growth, to 541 thousand, +13.9% year over year — the first evidence in this release that the behavioral base is stabilizing somewhere.
• Gross margin of 70.3% (73.6% adjusted) is described as near record highs and cost of revenue of $48.2m is roughly flat against the $46.5m predecessor stub despite a much smaller revenue base.
• Marketing spend fell to $47.9m from $92.9m in Q1 2026, and clinical subscribers were flat quarter over quarter despite that cut, which the company frames as deliberate recalibration rather than demand loss.
• The balance sheet was actively delevered: $36.8m of cash prepayments retired $41.4m of principal (a discount capture on the $10.0m May tranche at 68.5% of par) and cut annualized interest by about $4m; long-term debt fell 8.9% since year end to $424.0m.
• Operating cash flow was positive at $24.3m in the quarter, and management describes the business as cash accretive.
• Full-year revenue and adjusted EBITDA guidance were reaffirmed, so nothing in the quarter forced a cut.

Key bearish aspects

• On the company's own combined basis, revenue fell 14.2% year over year (−14.6% constant currency) and six-month revenue fell 12.0%; the consensus beat is against a low bar, not against growth.
• Behavioral subscription revenue, still 74.8% of total subscription revenue, fell 22.7% year over year to $121.5m and 20.1% for the six months.
• Total end-of-period subscribers fell 21.4% to 2,489 thousand and behavioral subscribers fell 24.6% to 2,291 thousand; incoming subscribers fell 22.6%, so the funnel entering the quarter was already smaller.
• Clinical monthly revenue per average subscriber fell 13.4% to $67.55, so clinical growth is being bought with lower price per user; the subscriber count is carrying that line, not pricing.
• Clinical end-of-period subscribers were flat sequentially against Q1 2026 after marketing spend was cut roughly in half, which leaves open whether clinical growth is spend-dependent.
• Cash fell 36.7% since year end to $101.5m, and total assets fell 11.2% to $840.4m; the debt paydown was funded from that cash balance.
• Accumulated deficit widened to $(100.0)m from $(62.1)m at year end even though the quarter posted net income, so the six-month period is a net loss on the successor basis.
• Reported operating income of $9.5m on $162.3m of revenue is a 5.8% operating margin, and $6.6m of net non-operating expense cut pre-tax income to $2.9m; the $14.1m of net income sits above operating income only because of an $11.2m tax benefit.
• Other intangible assets fell 7.6% to $453.3m in six months on fresh-start amortization, which the release cites as the reason depreciation and amortization is elevated; that amortization runs against reported earnings for several years.
• The company has no permanent chief executive; an Interim Office of the Chief Executive is running the business and the CEO transition is named as a risk factor.

Key uncertainties

• The release states the successor and predecessor financial statements are not comparable, and it presents combined comparatives only for revenue. Every non-revenue year-over-year comparison in this quarter is therefore unavailable from this document.
• The $11.155m income tax benefit drives most of the EPS beat; the release does not state the effective tax rate or explain what produced the benefit, and whether it repeats is unknown.
• Adjusted EBITDA of $39.8m and adjusted gross margin of 73.6% are cited in the narrative, but the reconciliation detail behind them was not read for this preliminary; the specific add-backs are not assessed here.
• The four lines between operating income and pre-tax income (reorganization items, interest expense, gain on extinguishment of debt, and other income/expense) could not be reliably attributed to their columns from the release document's extracted text, so they are shown only as a $6.555m combined net expense for the quarter; the split between interest cost and reorganization or debt-extinguishment items is not determinable here.
• Full-year revenue guidance of $620m-$635m against $330.6m of six-month revenue implies roughly $289m-$304m in the second half, below the first-half run rate; the release gives no bridge for the implied step-down.
• Core+ is disclosed only as an end-of-period subscriber count; its revenue, ARPU, and margin contribution are not broken out, so its 13.9% growth cannot be sized against the 22.7% behavioral revenue decline.
• The May 2026 term loan solicitation was "fully subscribed at 68.5% of par," but the release does not state what portion of the total term loan was eligible or whether further discounted repurchases are planned.
• The company reports 9,999 shares issued at a $0 par value with 1,000,000 shares authorized, and weighted-average diluted shares of 10,001 thousand against 81,165 thousand in the predecessor period; the post-emergence capital structure is not otherwise described here.
• Clinical growth laps the discontinued compounded semaglutide offering, and the release does not quantify how much prior-year clinical revenue came from that product, so the underlying growth rate is not determinable from this document.
• The 21:00Z call had not occurred at the time of this report; management's account of the second-half guidance path, the CEO search, and clinical marketing efficiency is not assessed at this stage.
• A shareholder letter was issued alongside this release and posted to the corporate website; it is not attached to this Quartr event and was not read.

Market context

• API Ninjas snapshot: WW $15.41 on NASDAQ, volume 390,892, quote timestamped 2026-08-05T20:12:37Z, retrieved 2026-08-05T20:33:00Z. The release was published after the U.S. close on 2026-08-05; this is a single quote of unstated session basis captured minutes after the close, not a measured reaction to the release.

Source limitations

• Every actual above comes from the Quartr Q2 2026 earnings release document (3670364). Quartr standardized financials for this event are not yet populated.
• API Ninjas supplied no actual or difference fields for this event, so each beat/miss is calculated locally as Quartr actual minus API Ninjas estimate. The API row carried no fiscal year or quarter, so the exact ticker-and-event-date match path was used.
• Percentage changes not printed in the release are calculated from the release's own columns; the balance-sheet change column compares 30 June 2026 to 31 December 2025, not to the prior-year quarter.
• Income-statement comparatives are the two stub periods the company presents. They are not summed here because the release states the successor and predecessor bases are not comparable; only the revenue lines carry a company-prepared combined comparative.
• The condensed consolidated statements in this release are unaudited.
• The extracted text of the statements of operations page did not preserve the column alignment of the four lines between operating income and pre-tax income. Rather than assign those figures to columns on inference, they are presented as one combined net non-operating amount per column, each derived as that column's operating income less its stated pre-tax income.
• Adjusted EBITDA, adjusted gross margin, gross margin, marketing as a percentage of revenue, operating cash flow, and the debt prepayment figures are quoted from the release narrative; the supporting reconciliation and cash-flow statement pages were not read for this preliminary.
• The release contains no segment table beyond the behavioral/clinical revenue split shown above.

Source links

• Quartr Q2 2026 earnings release
• Quartr release headline results page
• Quartr release balance sheet and liquidity page
• Quartr release balance sheet page
• Quartr release statements of operations page
• Quartr release combined revenue reconciliation page
• Quartr release operational statistics page